- Home
- INCY vs MNDY Comparison
INCY vs MNDY Comparison
Compare INCY & MNDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INCY
- MNDY
- Stock Information
- Founded
- INCY 1991
- MNDY 2012
- Country
- INCY United States
- MNDY Israel
- Employees
- INCY N/A
- MNDY N/A
- Industry
- INCY Biotechnology: Commercial Physical & Biological Resarch
- MNDY Computer Software: Prepackaged Software
- Sector
- INCY Health Care
- MNDY Technology
- Exchange
- INCY Nasdaq
- MNDY Nasdaq
- Market Cap
- INCY 13.4B
- MNDY 14.9B
- IPO Year
- INCY 1993
- MNDY 2021
- Fundamental
- Price
- INCY $65.06
- MNDY $297.49
- Analyst Decision
- INCY Hold
- MNDY Strong Buy
- Analyst Count
- INCY 19
- MNDY 24
- Target Price
- INCY $72.67
- MNDY $344.71
- AVG Volume (30 Days)
- INCY 1.8M
- MNDY 668.4K
- Earning Date
- INCY 04-29-2025
- MNDY 05-12-2025
- Dividend Yield
- INCY N/A
- MNDY N/A
- EPS Growth
- INCY N/A
- MNDY 145.64
- EPS
- INCY 0.10
- MNDY 1.00
- Revenue
- INCY $4,413,226,000.00
- MNDY $1,037,332,000.00
- Revenue This Year
- INCY $13.29
- MNDY $28.29
- Revenue Next Year
- INCY $10.43
- MNDY $23.34
- P/E Ratio
- INCY $592.09
- MNDY $296.79
- Revenue Growth
- INCY 17.13
- MNDY 32.25
- 52 Week Low
- INCY $53.56
- MNDY $188.01
- 52 Week High
- INCY $83.95
- MNDY $342.64
- Technical
- Relative Strength Index (RSI)
- INCY 60.01
- MNDY 60.33
- Support Level
- INCY $63.51
- MNDY $281.22
- Resistance Level
- INCY $66.26
- MNDY $302.35
- Average True Range (ATR)
- INCY 1.60
- MNDY 11.41
- MACD
- INCY 0.32
- MNDY -0.38
- Stochastic Oscillator
- INCY 83.12
- MNDY 83.18
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
About MNDY monday.com Ltd.
Monday.com is a provider of work management software delivered via a cloud-based software-as-a-service, or SaaS model. The firm's solutions offer flexible and highly customizable tools to digitize business processes across countless use cases. Monday's offering supports workflow management across departments, real-time visibility and accountability, and automation capabilities. Monday also offers prepackaged CRM and DevOps management solutions, in addition to standalone survey and digital whiteboard tools. As of 2023, Monday served over 225,000 customers in more than 200 countries.